UNSPSC 51192019: Allopurinol sodium

This classification denotes a xanthine oxidase inhibitor and uricosuric agen with the molecular formula C5H3N4O.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 428673RC2Z, chemically known as 1,5-dihydro-4h-pyrazolo(3,4-d)pyrimidine-4-one but more generally known as allopurinol sodium, which bears US NIH Compound Identifier 2094. The base compound, Allopurinol, comes in other forms, including di-methyl, ribonucleoside, riboside, riboside, and 5-monophosphate.

UNSPSC 51192019 Allopurinol sodium is a Commodity code for a specific pharmaceutical product — a urate oxidase inhibitor used to manage gout and hyperuricemia — yet the recent state and local opportunities tagged under this code show minimal pharmaceutical procurement activity directly aligned with the product itself. The three recent opportunities on file span athletic training services (City of Tucson), general medical aid supplies including first-aid items and over-the-counter pain relievers (City of Tampa Fire Rescue), and a Texas Health and Human Services Commission Request for Information on direct-to-manufacturer prescription programs. The Tampa Fire Rescue solicitation includes aspirin and pain relievers among 32 line items, but does not isolate allopurinol sodium. The code shows little relevant recent activity; the tagging appears to reflect either a broad categorization artifact or administrative misalignment between the solicitation scope and the code assignment.

The geographic spread across recent opportunities includes Arizona, Florida, and Texas, though these solicitations do not represent allopurinol sodium procurement in particular. The City of Tucson's RFP for athletic training services (Solicitation 260163, due June 9, 2026) and the City of Tampa Fire Rescue's ITB for medical aid supplies (Solicitation 25P00157, due April 9, 2025) target city agencies; the Texas HHS Commission's RFI (HHS0017013, response deadline April 3, 2026) represents state-level pharmaceutical benefit strategy development. State and local procurement of allopurinol sodium specifically—whether through standing orders, formulary agreements, or emergency medical supply contracts—does not appear in the current opportunities block. Firms pursuing this Commodity code should monitor state Medicaid formulary updates, county health department procurement channels, and hospital purchasing vehicles rather than rely on recent RFP or ITB activity to signal active demand.